On August 5, 2020, Congressman Josh Gottheimer helped lead a letter from the House Financial Services Committee calling on the Securities and Exchange Commission (SEC) to investigate the transactions surrounding the $765 million proposed deal under the Defense Production Act of 1950 (DPA) between the Administration and Eastman Kodak Company (Kodak) amid reports that Kodak’s compensation board issued $1.75 million in stock options to Executive Chairman and CEO Jim Continenza.

“Our country is already home to many successful life sciences companies — many located in my home state of New Jersey — with decades of experience and proven track records. Now is not the time to be placing bets of hundreds of millions of dollars, during a public health crisis no less, on unproven entities that are wholly unprepared to help our nation through this pandemic,” said Congressman Gottheimer (NJ-5) upon the release of this letter.     

Fueling the Members’ concern about insider training during the COVID-19 pandemic are SEC filings that indicate Continenza and Philippe Katz, a Kodak board member, bought Kodak shares on July 23, 2020 – just days before the DPA loan became public information.

“Our concerns regarding insider trading during the COVID-19 pandemic have only been heightened by our serious concerns arising from a series of securities transactions engaged in by Eastman Kodak Company (Kodak), its executive officers and its board members,” the Members wrote in the letter to SEC Chairman Jay Clayton. “These transactions seem to have taken place at, or around, the time Kodak learned it could be eligible to receive a $765 million loan under the Defense Production Act of 1950 (DPA). Notably, the loan was awarded to Kodak to manufacture generic drugs in the United States, despite Kodak’s limited experience in the pharmaceutical industry.”

Gottheimer was joined on the letter by Congresswoman Maxine Waters (D-CA), Chairwoman of the House Committee on Financial Services, Congressman Brad Sherman (D-CA), Chairman of the Subcommittee on Investor Protection, Entrepreneurship and Capital Markets, Congressman Gregory Meeks (D-NY), Chairman of the Subcommittee on Consumer Protection and Financial Institutions, Congressman Emanuel Cleaver (D-MO), Chairman of the Subcommittee on National Security, International Development and Monetary Policy, Congressman Bill Foster (D-IL), Chairman of the Task Force on Artificial Intelligence, and Congressman Stephen F. Lynch (D-MA), Chairman of the Task Force on Financial Technology, as well as Representatives Carolyn B. Maloney (D-NY), Nydia M. Velasquez (D-NY), Katie Porter (D-CA), and Cindy Axne (D-IA).

A copy of the letter is available HERE, the text of which is provided below.

The Honorable Jay Clayton
Chairman
US Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549

Dear Chair Clayton:

We are writing to express our growing concern regarding insider trading, during the coronavirus disease 2019 (COVID-19) pandemic. As Americans navigate through the COVID-19 pandemic, information about which publicly traded companies are affected by the pandemic; how they are affected; information about aid, loans or grants provided to these companies; and other nonpublic information, is more likely to be considered material, particularly when it comes to investors making investment decisions. Further, some bad actors may take advantage of these difficult times and unlawfully trade on this material, nonpublic information, harming market stability and the investing public. The US Securities and Exchange Commission (SEC or Commission) must remain vigilant in enforcing laws against insider trading.

Our concerns regarding insider trading during the COVID-19 pandemic have only been heightened by our serious concerns arising from a series of securities transactions engaged in by Eastman Kodak Company (Kodak), its executive officers and its board members. These transactions seem to have taken place at, or around, the time Kodak learned it could be eligible to receive a $765 million loan under the Defense Production Act of 1950 (DPA). Notably, the loan was awarded to Kodak to manufacture generic drugs in the United States, despite Kodak’s limited experience in the pharmaceutical industry.

In its 2019 annual report, Kodak explained that: “If Kodak is unable to generate positive cash flow from operations in the future or to adequately supplement such cash flow from operations with proceeds from monetization transactions, its ability to continue as a going concern could be impaired or limited.”[1] On May 1, 2020, the adjusted closing price for Kodak stock was $2.20. The Trump administration’s announcement that Kodak would receive the DPA loan caused the, then-failing, manufacturing company’s share price to increase to $33.20, on July 29, 2020 – the day after President Trump announced the DPA loan.[2] That amount is over fifteen times the stock’s May 1, 2020 value and provides a tremendous incentive for those who knew about the DPA loan to capitalize on that information before it became public.

Along those lines, around the same time the DPA loan was announced to the public, Kodak’s board, reportedly, issued 1.75 million in stock options to Jim Continenza, the company’s Executive Chairman and Chief Executive Officer.[3]Those options allow Continenza to purchase Kodak shares at prices ranging from $3.03 to $12[4] which, according to media reports, could net Continenza a $50 million profit.[5] Further, the options were issued under unusual circumstances in terms of the timing in that they were, reportedly, based on some peculiar and unwritten “understanding” between Continenza and the company.[6] Media reports, and SEC filings, further indicate that Continenza and Philippe Katz, a Kodak board member, bought 46,737 and 5,000 Kodak shares, respectively, on June 23, 2020.[7] At the time of these purchases, Kodak’s stock price was $2.22[8] but, as indicated above, would significantly increase in value after the DPA was announced. Most concerningly, it appears these purchases were made prior to the DPA loan becoming public information, but while Kodak was in discussions regarding the loan.

We urge the SEC to investigate these transactions and, during the course of that investigation, encourage it to consider the following:

 1. The facts, circumstances and terms under which Kodak issued, or re-issued, stock options to its executive officers or other company personnel between January 1, 2020 and August 1, 2020. 

 2. Whether Kodak’s issuance, or re-issuance, of stock options to any executive officer or company personnel, violated Kodak’s polices, including its Executive Compensation Committee Board of Directors Eastman Kodak Company Policy on Equity Awards. The policy, among other things, prohibits manipulating the timing of any public release of “material information or of any Equity Award with the intent of benefiting a grantee under an Equity Award.”[9] 

 3. The date on which discussions, whether formal or informal, regarding the DPA loan commenced.

 4. The identities of all Kodak executives, officers and major shareholders who were aware that Kodak may receive the DPA loan, and the dates on which they became aware of this information. 

 5. Steps, if any, taken by Kodak to prohibit and/or monitor trading of Kodak stock by Kodak’s executives, directors and major shareholders. 

 6. Transactions engaged in by Kodak executives, officers or major shareholders between the date the DPA loan discussions first commenced and the date the DPA loan was publicly announced (Transactions). 

 7. Profit, if any, derived from the Transactions. 

The capital markets are at their best when transactions are entered into by and between informed buyers and informed sellers. Insider trading undermines public trust in our capital markets and cannot be tolerated, particularly at a time when trust and confidence in the markets are vital to our economy’s future recovery. 

Sincerely,

The Honorable Maxine Waters
Chairwoman
House Committee on Financial Services

The Honorable Josh Gottheimer
Member of Congress

The Honorable Brad Sherman
Chairman
Subcommittee on Investor Protection, Entrepreneurship and Capital Markets

The Honorable Nydia M. Velázquez
Member of Congress

The Honorable Emanuel Cleaver
Chairman
Subcommittee on National Security, International Development and Monetary Policy

The Honorable Bill Foster
Chairman
Task Force on Artificial Intelligence 

The Honorable Stephen F. Lynch
Chairman
Task Force on Financial Technology 

The Honorable Carolyn B. Maloney
Member of Congress

The Honorable Katie Porter
Member of Congress

The Honorable Cindy Axne
Member of Congress

The Honorable Gregory W. Meeks
Chairman
Subcommittee on Consumer Protection and Financial Institutions 

Cc: The Honorable Patrick McHenry, Ranking Member, House Committee on Financial Services
The Honorable Bill Huizenga, Ranking Member, Subcommittee on Investor Protection, Entrepreneurship and Capital Markets
The Honorable J. French Hill, Ranking Member, Subcommittee on National Security, International Development and Monetary Policy
The Honorable Barry Loudermilk, Ranking Member, Task Force on Artificial Intelligence
The Honorable Tom Emmer, Ranking Member, Task Force on Financial Technology
The Honorable Blaine Luetkemeyer, Ranking Member, Subcommittee on Consumer Protection and Financial Institutions 

__________________________

[1] See Eastman Kodak Company 2019 Annual Report on Form 10-K and Notice of 2020 Annual Meeting and Proxy Statement, available at https://www.annualreports.com/HostedData/AnnualReports/PDF/NASDAQ_KODK_2019.pdf.

[2] See Kodak’s stock tumbles again, after disclosure that investors have converted debt into nearly 30 million common shares, Marketwatch.com, Aug. 3, 2020, available at https://www.marketwatch.com/story/kodaks-stock-tumbles-again-after-disclosing-investors-have-converted-debt-into-nearly-30-million-common-shares-2020-08-03 (as of Aug. 4, 2020).

[3] See Kodak C.E.O. Got Stock Options Day Before News of Loan Sent Stock Soaring, New York Times, July 31, 2020, available at https://www.nytimes.com/2020/07/31/business/kodak-ceo-stock-options.html (as of Aug. 4, 2020).

[4] Id.

[5] Id. Kodak’s stock price has fallen since the date of this article and, thus, the value of Continenza’s options are, currently, lower. The value may, however, increase or decrease over time.

[6] See Eastman Kodak’s Top Executive Reportedly Got Trump Deal Windfall On An ‘Understanding,’ CNBC, August 3, 2020, available at https://www.cnbc.com/2020/08/01/eastman-kodaks-top-executive-reportedly-got-trump-deal-windfall-on-an-understanding.html (as of August 4, 2020).

[7] See Kodak CEO admits he bought thousands of shares in the fallen photo firm AFTER taking part in secret talks to turn company into pharma giant with $768M government loan – making $1.5m personal profit, Daily Mail, July 30, 2020, available at https://www.dailymail.co.uk/news/article-8576731/Kodak-CEO-admits-talks-turn-photo-giant-pharma-company-began-month-bought-shares.html (as of Aug. 4, 2020).

[8] Id.

[9] See Executive Compensation Committee Board of Directors Eastman Kodak Company Policy on Equity Awards, at p. 1, available at https://investor.kodak.com/static-files/c50b6eaa-79c0-4781-8f51-85ec1e6bc416.

###